1. A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI.
- Author
-
Shih TL, Lin KH, Chen RJ, Chen TY, Kao WT, Liu JW, Wang HH, Peng HY, Sun YY, and Lu WJ
- Subjects
- Adenosine Triphosphate metabolism, Animals, Calcium metabolism, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Immunohistochemistry, Male, Mice, Microvessels drug effects, Microvessels metabolism, Microvessels pathology, Molecular Structure, Naphthalimides chemistry, Platelet Aggregation drug effects, Signal Transduction, Thrombosis drug therapy, Thrombosis etiology, Thrombosis pathology, Blood Platelets drug effects, Blood Platelets metabolism, Naphthalimides pharmacology, Platelet Activation drug effects, Platelet Aggregation Inhibitors pharmacology, Platelet Membrane Glycoproteins metabolism, Thrombosis metabolism
- Abstract
Naphthalimide derivatives have multiple biological activities, including antitumour and anti-inflammatory activities. We previously synthesized several naphthalimide derivatives; of them, compound 5 was found to exert the strongest inhibitory effect on human DNA topoisomerase II activity. However, the effects of naphthalimide derivatives on platelet activation have not yet been investigated. Therefore, the mechanism underlying the antiplatelet activity of compound 5 was determined in this study. The data revealed that compound 5 (5-10 μM) inhibited collagen- and convulxin- but not thrombin- or U46619-mediated platelet aggregation, suggesting that compound 5 is more sensitive to the inhibition of glycoprotein VI (GPVI) signalling. Indeed, compound 5 could inhibit the phosphorylation of signalling molecules downstream of GPVI, followed by the inhibition of calcium mobilization, granule release and GPIIb/IIIa activation. Moreover, compound 5 prevented pulmonary embolism and prolonged the occlusion time, but tended to prolong the bleeding time, indicating that it can prevent thrombus formation but may increase bleeding risk. This study is the first to demonstrate that the naphthalimide derivative compound 5 exerts antiplatelet and antithrombotic effects. Future studies should modify compound 5 to synthesize more potent and efficient antiplatelet agents while minimizing bleeding risk, which may offer a therapeutic potential for cardiovascular diseases., (© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF